MLN 0415

Drug Profile

MLN 0415

Alternative Names: MLN0415; SAR 479746

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Takeda
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arthritis; Inflammation

Most Recent Events

  • 14 May 2008 Takeda acquires Millennium
  • 30 Aug 2006 Phase-I clinical trials in Inflammation in USA (PO)
  • 02 Nov 2005 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top